Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.

ABSTRACT:

Background

Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT_1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine disability assessed with the Migraine Disability Assessment (MIDAS) scale for interim data from a long-term safety study.

Methods

Completers of two single-attack parent studies were offered participation in the 1 year GLADIATOR study, that randomized participants to treatment with lasmiditan 100 mg or 200 mg taken as needed for migraine attacks of at least moderate severity. Changes in MIDAS were modeled using a mixed model repeated measures analysis.

Results

The sample included 1978 patients who received ≥1 lasmid

SUBMITTER: Lipton RB 

PROVIDER: S-EPMC7041198 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature